Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03263936
Title Epigenetic Reprogramming in Relapse/Refractory AML
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Therapeutic Advances in Childhood Leukemia Consortium
Indications

acute myeloid leukemia

Therapies

Vorinostat

Decitabine

Cytarabine

Fludarabine

Filgrastim

Age Groups: adult | child
Covered Countries USA | CAN


No variant requirements are available.